Impact Factor
3.01
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.72
243 total citations
h5-index
21
h5 depth signal
Cited share
69.8%
104 of 149
Total citations
243
Citation footprint
Metric signal
2.50
External metric anchor
Self-citation
12.3%
30 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
391
China
153
Netherlands
76
Italy
68
Spain
67
Citing Fields of Research
Genetics & Genomics
422
Pharmacology & Toxicology
381
Cardiology
127
Psychiatry
106
Oncology
101
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,581
Articles tracked across the journal lifetime
Indexed publication set
149
104 cited publications
Last 12 months
71
7.1 publications/month
Open access share
11.3%
8 OA publications in the last year
Leading citing country
United States
391 citing publications
Leading citing field
Genetics & Genomics
422 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Feb. 2000-
v1n1, Feb. 2000-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Genetics & Genomics
Pharmacology & Toxicology
Cardiology
Psychiatry
Hematology
Broad Categories
Genetics, Medical
Pharmacology
Genetics & Genomics
Pharmacology & Toxicology
Cardiology
Transplantation
Allergies
MeSH Descriptors
Genomics
Pharmacogenetics
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14622416.2026.2746614
Open DOI
Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines
02
DOI 10.1080/14622416.2026.2710146
Open DOI
Mapping the development pipeline of genomic point-of-care tests: a horizon scan
03
DOI 10.1080/14622416.2026.2732153
Open DOI
Pharmacogenomics of cancer therapy-related cardiomyopathy in childhood cancer survivors
1. There is an increasing number of long-term survivors that have resulted from the improvements that have been made in childhood cancer treatment, especially over the past 5 decades. As this popul...
04
DOI 10.1080/14622416.2026.2738672
Open DOI
Pharmacogenomics utilization as a tool for deprescribing in Veterans at high-risk for polypharmacy
1. With the aging population of Veterans, it is important to ensure medication regimens are optimized. Patients are started on medications that were once appropriate, but as they age, the appropria...
05
DOI 10.1080/14622416.2026.2738674
Open DOI
Analysis of the influence of rs1801265 polymorphism on DPD enzyme activity and contributing factors in the Chinese population
06
DOI 10.1080/14622416.2026.2736305
Open DOI
Process evaluation of a pharmacogenomic informed antidepressant prescribing intervention delivered in primary care: findings from the PRESIDE (PhaRmacogEnomicS in Depression) trial
Major depressive disorder (MDD) impacts 300 million people globally, with most people being managed in primary care. Clinical response to antidepressant medications is highly variable. Pharmacogenomics (PGx) may improve prescribers' abil...
07
DOI 10.1080/14622416.2026.2730713
Open DOI
Associations of SLCO gene polymorphisms with perampanel response and plasma concentrations in patients: a longitudinal retrospective real-world study in refractory epilepsy
1. The primary approach for epilepsy management involves the prolonged administration of anti-seizure medications (ASMs) [1]. However, more than 30% of patients are unable to control their seizures...
08
DOI 10.1080/14622416.2026.2738673
Open DOI
The role of pharmacogenomics in effective pain management with opioids
1. Pain is a prevalent condition that can be challenging to manage, partly because it is influenced by subjective individual experiences [1]. Interindividual variability in pain perception and anal...
09
DOI 10.1080/14622416.2026.2729992
Open DOI
The influence of pharmacogenetics on the treatment-related outcomes of antidepressants and antipsychotics in Brazil: a systematic review
1. Pharmacogenetics examines how genetic variants influence therapeutic responses to medications, thereby contributing to interindividual variability in treatment outcomes. By identifying genes inv...
10
DOI 10.1080/14622416.2026.2732154
Open DOI
Pharmacogenomics and artificial intelligence in cardiovascular disease: emerging tools for precision medicine
1. CVD are among the major causes of mortality and morbidity worldwide, with a significant impact on the lives of millions of people annually. According to the World Health Organization data, CVDs ...
Bibliographical & Catalog Notes
Description based on: Vol. 1, no. 4 (Nov. 2000); title from cover.
Latest issue consulted: Vol. 3, no. 3 (May 2002).
Also issued online.
v. 1, no. 1 (Feb. 2000)20010501 Notice not published Printed on acid-free paper